NCT00576654: Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Only BRCA+ TNBC patients will be eligible for phase 2
Exclusions: Patients with known active brain metastases- see trial for details

Comments are closed.

Up ↑